article = {JICOA-2020-4-110}
title = {ApoL6: A Novel Biomarker of Apoptotic and Necroptotic Activity in Evolving STsegment Myocardial Infarction in Man}
journal = {Journal of Integrative Cardiology Open Access}
year = {2020}
issn = {2674-2489}
doi = {http://dx.doi.org/10.31487/j.JICOA.2020.04.10}
url = {https://www.sciencerepository.org/apol6-a-novel-biomarker-of-apoptotic-activity-in-evolving-st_JICOA-2020-4-110 
author = {Chien-An Andy Hu,Siqin  Zhaorigetu,W Sean  Davidson,Warren  Laskey,}
keywords = {Apolipoprotein L6 (ApoL6), apoptosis, myocardial infarction, necroptosis}
abstract ={We have previously demonstrated that apolipoprotein L6 (ApoL6) is a pro-death, phospholipid-binding,
BH3-only member of the Bcl-2 family. Ectopic expression of ApoL6 induces dichotomous cell death
phenotype involving both apoptosis and necroptosis in various cell types. In addition, ApoL6 initiates
inflammatory response that upregulates proinflammatory cytokines, such as IL-1β. In this study, we show
elevated levels of ApoL6 in the sera of the majority of ST-segment myocardial infarction (STEMI) patients
prior to reperfusion which is highly suggestive of the activation of apoptotic and/or necroptotic pathways in
ruptured plaque. Thus, ApoL6 could serve as a biomarker specific for inflammatory apoptotic and/or
necroptotic activity in STEMI, as well as other diseases.}